Skip to main content
. 2017 Feb 21;11:469–481. doi: 10.2147/DDDT.S124102

Figure 3.

Figure 3

The concentration of imatinib mesylate that is required for 50% inhibition of two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A proliferation (half minimal inhibitory concentration) after 144 h treatment compared to untreated cell lines.

Note: *P<0.05 was considered as significant.